Activation of endogenous angiotensin converting enzyme 2 prevents early injuries induced by hyperglycemia in rat retina

Brazilian Journal of Medical and Biological Research

Volumn 48, Issue 12, 2015, Pages 1109-1114

  Foureaux, G ^a   Nogueira, B S ^a   Coutinho, D C O ^a   Raizada, M K ^b   Nogueira, J C ^a   Ferreira, A J ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

ACE2 activation; Angiotensin (1 7); Diabetic retinopathy; Eyes; Renin angiotensin system

Indexed keywords

1 [[2 (DIMETHYLAMINO) ETHYL] AMINO] 4 (HYDROXYMETHYL) 7 [[(4 METHYLPHENYL) SULFONYL] OXY] 9H XANTHONE 9; ANGIOTENSIN CONVERTING ENZYME 2; CASPASE 3; STREPTOZOCIN; UNCLASSIFIED DRUG; VASCULOTROPIN; XANTHONE DERIVATIVE; 1-((2-DIMETHYLAMINO)ETHYLAMINO)-4-(HYDROXYMETHYL)-7-((4-METHYLPHENYL)SULFONYLOXY)-9H-XANTHENE-9-ONE; DIPEPTIDYL CARBOXYPEPTIDASE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; HISTOLOGY; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; RETINA GANGLION CELL; RETINA INJURY; ANIMAL; APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHYSIOLOGY; PROCEDURES; RETINAL DISEASES; SECONDARY PREVENTION; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; APOPTOSIS; CASPASE 3; CELL PROLIFERATION; CELL SURVIVAL; DIABETES MELLITUS, EXPERIMENTAL; ENZYME ACTIVATION; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; MALE; PEPTIDYL-DIPEPTIDASE A; RATS, WISTAR; RETINAL DISEASES; RETINAL GANGLION CELLS; SECONDARY PREVENTION; STREPTOZOCIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XANTHONES;

EID: 84945301124     PISSN: None     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/1414-431X20154583     Document Type: Article

References (40)

1. Bosco LA, Soriano D, Santos RF, Massote P, Galvão D, Franco AC, et al. Retinopatia diabética. Arq Bras Endocrinol Metabol 2005; 49: 217–227, doi: 10.1590/S0004-27302005000200007
2. Kuper H, Polack S, Limburg H. Rapid assessment of avoidable blindness. Community Eye Health 2006; 19: 68–69
3. Chakrabarti RHC, Keeffe JE. Diabetic retinopathy management guidelines. Exp Rev Ophthalmol 2012; 75: 417–439, doi: 10.1586/eop.12.52
4. Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 2003; 26: 2653–2664, doi: 10.2337/diacare.26.9.2653
5. Curtis TM, Gardiner TA, Stitt AW. Microvascular lesions of diabetic retinopathy: clues towards understanding pathogenesis? Eye 2009; 23: 1496–1508, doi: 10.1038/eye.2009.108
6. Park SH, Park JW, Park SJ, Kim KY, Chung JW, Chun MH, et al. Apoptotic death of photoreceptors in the streptozotocin- induced diabetic rat retina. Diabetologia 2003; 46: 1260–1268, doi: 10.1007/s00125-003-1177-6
7. Senanayake P, Drazba J, Shadrach K, Milsted A, Rungger- Brandle E, Nishiyama K, et al. Angiotensin II and its receptor subtypes in the human retina. Invest Ophthalmol Vis Sci 2007; 48: 3301–3311, doi: 10.1167/iovs.06-1024
8. Raczynska D, Zorena K, Urban B, Zalewski D, Skorek A, Malukiewicz G, et al. Current trends in the monitoring and treatment of diabetic retinopathy in young adults. Mediators Inflamm 2014; 2014: 492926, doi: 10.1155/2014/492926
9. Tikellis C, Johnston CI, Forbes JM, Burns WC, Thomas MC, Lew RA, et al. Identification of angiotensin converting enzyme 2 in the rodent retina. Curr Eye Res 2004; 29: 419–427, doi: 10.1080/02713680490517944
10. Danser AH, Derkx FH, Admiraal PJ, Deinum J, de Jong PT, Schalekamp MA. Angiotensin levels in the eye. Invest Ophthalmol Vis Sci 1994; 35: 1008–1018
11. Fletcher EL, Phipps JA, Ward MM, Vessey KA, Wilkinson- Berka JL. The renin-angiotensin system in retinal health and disease: Its influence on neurons, glia and the vasculature. Prog Retin Eye Res 2010; 29: 284–311, doi: 10.1016/j.preteyeres.2010.03.003
12. Vaajanen A, Lakkisto P, Virtanen I, Kankuri E, Oksala O, Vapaatalo H, et al. Angiotensin receptors in the eyes of arterial hypertensive rats. Acta Ophthalmol 2010; 88: 431–438, doi: 10.1111/aos.2010.88.issue-4
13. Verma A, Shan Z, Lei B, Yuan L, Liu X, Nakagawa T, et al. ACE2 and Ang-(1-7) confer protection against development of diabetic retinopathy. Mol Ther 2012; 20: 28–36, doi: 10.1038/mt.2011.155
14. Ciudin A, Hernandez C, Simo R. Iron overload in diabetic retinopathy: a cause or a consequence of impaired mechanisms? Exp Diabetes Res 2010; 2010
15. Giese MJ, Speth RC. The ocular renin-angiotensin system: a therapeutic target for the treatment of ocular disease. Pharmacol Ther 2014; 142: 11–32, doi: 10.1016/j.pharmthera.2013.11.002
16. Zhang JZ, Xi X, Gao L, Kern TS. Captopril inhibits capillary degeneration in the early stages of diabetic retinopathy. Curr Eye Res 2007; 32: 883–889, doi: 10.1080/02713680701584123
17. Wright AD, Dodson PM. Diabetic retinopathy and blockade of the renin-angiotensin system: new data from the DIRECT study programme. Eye 2010; 24: 1–6, doi: 10.1038/eye.2009.189
18. Ghattas A, Lip PL, Lip GY. Renin-angiotensin blockade in diabetic retinopathy. Int J Clin Pract 2011; 65: 113–116
19. Foureaux G, Nogueira JC, Nogueira BS, Fulgencio GO, Menezes GB, Fernandes SO, et al. Antiglaucomatous effects of the activation of intrinsic Angiotensin-converting enzyme 2. Invest Ophthalmol Vis Sci 2013; 54: 4296–4306, doi: 10.1167/iovs.12-11427
20. Qiu Y, Shil PK, Zhu P, Yang H, Verma A, Lei B, et al. Angiotensin-converting enzyme 2 (ACE2) activator diminazene aceturate ameliorates endotoxin-induced uveitis in mice. Invest Ophthalmol Vis Sci 2014; 55: 3809–3818, doi: 10.1167/iovs.14-13883
21. Ferreira AJ, Shenoy V, Yamazato Y, Sriramula S, Francis J, Yuan L, et al. Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med 2009; 179: 1048–1054, doi: 10.1164/rccm.200811-1678OC
22. Ferreira AJ, Shenoy V, Qi Y, Fraga-Silva RA, Santos RA, Katovich MJ, et al. Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. Exp Physiol 2011; 96: 287–294, doi: 10.1113/expphysiol.2010.055277
23. Fraga-Silva RA, Sorg BS, Wankhede M, deDeugd C, Jun JY, Baker MB, et al. ACE2 activation promotes antithrombotic activity. Mol Med 2010; 16: 210–215
24. Fraga-Silva RA, Costa-Fraga FP, Murca TM, Moraes PL, Martins LA, Lautner RQ, et al. Angiotensin-converting enzyme 2 activation improves endothelial function. Hypertension 2013; 61: 1233–1238, doi: 10.1161/HYPERTENSIONAHA.111.00627
25. Murca TM, Almeida TC, Raizada MK, Ferreira AJ. Chronic activation of endogenous angiotensin-converting enzyme 2 protects diabetic rats from cardiovascular autonomic dysfunction. Exp Physiol 2012; 97: 699–709, doi: 10.1113/expphysiol.2011.063461
26. Murca TM, Moraes PL, Capuruco CA, Santos SH, Melo MB, Santos RA, et al. Oral administration of an angiotensinconverting enzyme 2 activator ameliorates diabetes-induced cardiac dysfunction. Regul Pept 2012; 177: 107–115, doi: 10.1016/j.regpep.2012.05.093
27. Sramek SJ, Wallow IH, Tewksbury DA, Brandt CR, Poulsen GL. An ocular renin-angiotensin system. Immunohistochemistry of angiotensinogen. Invest Ophthalmol Vis Sci 1992; 33: 1627–1632
28. Rojanapongpun P, Drance SM, Morrison BJ. Ophthalmic artery flow velocity in glaucomatous and normal subjects. Br J Ophthalmol 1993; 77: 25–29
29. Wagner J, Jan Danser AH, Derkx FH, de Jong TV, Paul M, Mullins JJ, et al. Demonstration of reninmRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system. Br J Ophthalmol 1996; 80: 159–163
30. Savaskan E, Loffler KU, Meier F, Muller-Spahn F, Flammer J, Meyer P. Immunohistochemical localization of angiotensin- converting enzyme, angiotensin II and AT1 receptor in human ocular tissues. Ophthalmic Res 2004; 36: 312–320, doi: 10.1159/000081633
31. Luhtala S, Vaajanen A, Oksala O, Valjakka J, Vapaatalo H. Activities of angiotensin-converting enzymes ACE1 and ACE2 and inhibition by bioactive peptides in porcine ocular tissues. J Ocul Pharmacol Ther 2009; 25: 23–28, doi: 10.1089/jop.2008.0081
32. Haber PK, Ye M, Wysocki J, Maier C, Haque SK, Batlle D. Angiotensin-converting enzyme 2-independent action of presumed angiotensin-converting enzyme 2 activators: studies in vivo, ex vivo, and in vitro. Hypertension 2014; 63: 774–782, doi: 10.1161/HYPERTENSIONAHA.113.02856
33. Lieth E, Gardner TW, Barber AJ, Antonetti DA. Retinal neurodegeneration: early pathology in diabetes. Clin Experiment Ophthalmol 2000; 28: 3–8, doi: 10.1046/j.1442-9071.2000.00222.x
34. Oshitari T, Roy S. Diabetes: A potential enhancer of retinal injury in rat retinas. Neurosci Lett 2005; 390: 25–30, doi: 10.1016/j.neulet.2005.07.057
35. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 1998; 102: 783–791, doi: 10.1172/JCI2425
36. Kern TS, Barber AJ. Retinal ganglion cells in diabetes. J Physiol 2008; 586: 4401–4408, doi: 10.1113/jphysiol.2008.156695
37. Yan HT, Su GF. Expression and significance of HIF-1 alpha and VEGF in rats with diabetic retinopathy. Asian Pac J Trop Med 2014; 7: 237–240
38. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med 2012; 366: 1227–1239
39. Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007; 171: 53–67
40. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 26: 999–1005, doi: 10.1097/01.iae.0000247165.38655.bf.